Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Robotic Oncology appears to be the brand and web presence for the urology and prostate cancer practice of David B. Samadi, MD, rather than a drug-development biotech company. The organization focuses on robotic and minimally invasive urologic oncology care, especially robotic prostatectomy for prostate cancer, and promotes Dr. Samadi’s proprietary SMART (Samadi Modified Advanced Robotic Technique) surgical approach. Its services span prostate cancer treatment, prostate biopsy, focal therapy, PSA screening and monitoring, bladder cancer care, and related men’s health and urinary services. The business is best characterized as a private commercial healthcare provider and surgical practice operating in New York, with additional presence in East Hills, rather than as a therapeutics company with a pharmaceutical pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Robotic Oncology.